



IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 05-403)

In the Application of:

Christophe Revirron

Serial No.: 10/536,939

Filing Date: May 27, 2005

For: Use of Levocetirizine for the Treatment of
Persistent Allergic Rhinitis

Examiner: TBD

Group Art Unit: TBD

Confirmation No.: TBD

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In regard to the above identified application,

1. We are transmitting herewith the attached:

- a) Information Disclosure Statement;
- b) PTO Form 1449 and 12 references cited therein; and
- c) return receipt postcard.


2. With respect to fees:

- a) A fee is not required at this time.
- b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.

3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on December 16, 2005.

Date: December 16, 2005

Respectfully submitted,



Michael S. Greenfield
Registration No. 37,142



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 05-403)

PATENT

In the Application of:

Christophe Revirron

Serial No.: 10/536,939

Filing Date: May 27, 2005

For: Use of Levocetirizine for the Treatment of
Persistent Allergic Rhinitis

Examiner: TBD

Group Art Unit: TBD

Confirmation No.: TBD

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner of Patents and Trademarks
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the cited references are enclosed. These references are also listed on the enclosed PTO Form 1449.

This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.


FOREIGN PATENT DOCUMENTS

1. WO Patent No. WO 94/06429, published March 31, 1994.

CERTIFICATE OF MAILING (37 C.F.R. 1.8a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on December 16, 2005.

Date: December 16, 2005


Michael Greenfield


OTHER DOCUMENTS

2. Bousquet, et al., "The management of allergic rhinitis symptoms in the pharmacy", *Aria in the Pharmacy, Allergic Rhinitis and it's Impact on Asthmas*, pp. 1-25 FINAL DRAFT.
3. Storms, William W., "Rethinking our approach to allergic rhinitis management", *Ingentaconnect, Annals of Allergy, Asthma and Immunology*, Vol. 88, Supplement 1, April 2002, Abstract.
4. Gensthaller et al., "R-Enantiomer gegen Allergien" *Levocetirizin XP-001147797* pp. 35-36.
5. Juniper, Elisabeth F., "Measuring Health-Related Quality of Life in Rhinitis", *J Allergy Clin Immunol*, February 1997.
6. Juniper, Elisabeth F. and Guyatt, G.H., "Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis", *Clinical and Experimental Allergy*, Vol. 21, pp. 77-83, submitted 6 June 1990; revised 13 August 1990; accepted 13 August 1990.
7. Gandon, J.M and Allain, H., "Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers". 2002 Blackwell Science Ltd *Br J. Clin Pharmacol*, 54, 51-58.
8. Grant et al., "A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and flare response during 24 hours in healthy male subjects, *Annals of Allergy, Asthma & Immunology*. pp. 190-197.
9. Mees et al., "Efficacy and safety of levocetirizine in seasonal allergic rhinitis", *PubMed, Acta Otorhinolaryngol Belg.* 2001;55(4):305-12.
10. Doctor's Guide, "Xyzal (Levocetirizine) Launched in England for Allergic Rhinitis", <http://www.pslgroup/dg/207766.htm>, October 1, 2001.
11. Doctor's Guide, "Germany Approves Antihistamines Xyzal and Xusal (Levocetirizine)", <http://www.pslgroup.com/dg/1EFC66.htm>, January 16, 2001.
12. Salumun, et al., "Antihistamines in late-phase clinical development for allergic disease", *Expert Opinion, Investigation Drugs* (2002) 11(2):259-273.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff

Date: December 16, 2005

By:


Michael S. Greenfield
Reg. No. 37,142

Telephone: 312-913-0001
Facsimile: 312-913-0002

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive, 32nd Floor
Chicago, IL 60606

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use several sheets if necessary)

Atty. Docket No.

05-403

Serial No.

10/536,939

Applicant:

Christophe Revirron

Filing Date:

May 27, 2005

Group:

TBD

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	1.	WO 94/06429	31 March 1994	WO	31	495	✓	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	2.	Bousquet, et al., "The management of allergic rhinitis symptoms in the pharmacy", Aria in the Pharmacy, Allergic Rhinitis and its Impact on Asthmas, pp. 1-25 FINAL DRAFT.
	3.	Storms, William W., "Rethinking our approach to allergic rhinitis management", Ingentaconnect, Annals of Allergy, Asthma and Immunology, Vol. 88, Supplement 1, April 2002, Abstract.
	4.	Gensthaler et al., "R-Enantiomer gegen Allergien" Levocetirizin XP-001147797 pp. 35-36.
	5.	Juniper, Elisabeth F., "Measuring Health-Related Quality of Life in Rhinitis", J Allergy Clin Immunol, February 1997.
	6.	Juniper, Elisabeth F. and Guyatt, G.H., "Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis", Clinical and Experimental Allergy, Vol. 21, pp. 77-83, submitted 6 June 1990; revised 13 August 1990; accepted 13 August 1990.

	7.	Gandon, J.M and Allain, H., "Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers". 2002 Blackwell Science Ltd Br J. Clin Pharmacol, 54, 51-58.
	8.	Grant et al., "A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and flare response during 24 hours in healthy male subjects, Annals of Allergy, Asthma & Immunology. pp. 190-197.
	9.	Mees et al., "Efficacy and safety of levocetirizine in seasonal allergic rhinitis", PubMed, Acta Otorhinolaryngol Belg. 2001;55(4):305-12.
	10.	Doctor's Guide, "Xyzal (Levocetirizine) Launched in England for Allergic Rhinitis", http://www.pslgroup/dg/207766.htm , October 1, 2001.
	11.	Doctor's Guide, "Germany Approves Antihistamines Xyzal and Xusal (Levocetirizine)", http://www.pslgroup.com/dg/1EFC66.htm , January 16, 2001.
	12.	Salumun, et al., "Antihistamines in late-phase clinical development for allergic disease", Expert Opinion, Investigation Drugs (2002) 11(2):259-273.
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.